The U.S. Food and Drug Administration favors enacting a mandatory opioid-prescribing training program for dispensers of the extended-release and long-acting analgesics
ACR/ARHP Annual Meeting 2012: Federal Act Aims to Make New Biologic Drugs Available to Rheumatology Patients at a Lower Cost
The Biologics Price Competition and Innovation Act of 2009 would spur the development of products intended to be biosimilar to approved therapies
Rheumatology Drug Updates
Information on new approvals and medication safety that rheumatologists need to know
Panel Addresses Drug Safety Issues in Rheumatology Products
Black box warnings, TNF inhibitors, and tofacitinib discussed
Rheumatology Drug Updates
Information on new approvals and medication safety rheumatologists need to know
Rheumatology Drug Updates: Apremilast, Golimumab, and More
Information on new approvals and medication safety rheumatologists need to know
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
Medical Device Safety Concerns Rheumatologists
Are recent controversies over metal-on-metal hip replacements and an IOM report cause for worry?
FDA Seeks Comments on Drug Shortages
As reported last month (“Rheumatologists Struggle with Drug Shortages,” October 2011, p. 51), a bill (S. 296) proposed in the U.S. Senate would require drug manufacturers to notify the U.S. Food and Drug Administration (FDA) of factors that might lead to a drug shortage.
Clinical Trials Go Global
As medical research expands to the global population, will trial results sill apply to U.S. populations?
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- 29
- Next Page »